Whitaker Brothers Introduces the Ultimate Data Destruction Solution: The Datastroyer DCS 36/7 High Security COMBO Paper, CD, DVD, and Blu-ray Shredder
Datastroyer DCS 36/7 key features include:
- Shreds confidential documents into tiny 0.8 mm x 5 mm particles, so sensitive information is completely irrecoverable.
- Exceeds the highest level of security for data destruction by the NSA.
- Controlled Unclassified Information (CUI) compliant.
- Quickly shreds up to 14 sheets of paper at once, with an NSA volume rating of HIGH.
- Shreds credit cards and optical media like CDs, DVDs, and Blu-ray discs into 2 mm x 2 mm particles.
- NSA evaluated and listed on the July 2025 NSA/CSS Evaluated Products List.
Whitaker Brothers created this groundbreaking design to offer government agencies, businesses, and organizations of all sizes an all-in-one solution for securely eradicating both paper documents and optical media. 'We're thrilled that the DCS 36/7 is the latest addition to the NSA/CSS Evaluated Products List in July 2025,' writes Lauren Rossi, Vice President of Government Sales at Whitaker Brothers.
'The Datastroyer DCS 36/7 represents a significant advancement in our commitment to providing state-of-the-art data destruction equipment. Its powerful performance, high security ratings, and ease of use makes the Datastroyer DCS 36/7 the best tool to ensure both compliance and confidentiality,' said Joe Mitchell, President at Whitaker Brothers.
'This machine is a game changer for those that need to quietly and safely dispose of both physical and digital forms of confidential information, and it eliminates the need for purchasing separate shredders for paper and media, which saves time and space,' explains Kyle Mitchell, Vice President of National Sales at Whitaker Brothers.
Additional features of the shredder include anti-jam technology, a user-friendly touch screen, an integrated automatic oiler, and an eco-friendly energy management and control system. The Datastroyer DCS 36/7 High Security COMBO Paper, CD, DVD, and Blu-ray Shredder is now available for purchase through Whitaker Brothers' website by visiting whitakerbrothers.com/dcs367.
About Whitaker Brothers
Whitaker Brothers has been a top name in the data destruction and print finishing industries for over 80 years. Specializing in high-security shredders, Whitaker Brothers supplies a full collection of data destruction equipment and print finishing equipment produced to assist organizations and businesses protect their classified information, comply with privacy regulations, mitigate the risks associated with data breaches, and efficiently handle their paper needs. Because of its focus on innovation, quality, and customer service, Whitaker Brothers continues to be a catalyst in the industries in which it operates.
Press Contacts
For questions or more information, please contact:
Lauren Rossi
Vice President of Government Sales, Whitaker Brothers
[email protected]
Kyle Mitchell
Vice President of National Sales, Whitaker Brothers
[email protected]
Contact Information:
Whitaker Brothers Business Machines
Lauren Rossi
301-354-3044
Contact via Email
www.whitakerbrothers.com
Read the full story here: Whitaker Brothers Introduces the Ultimate Data Destruction Solution: The Datastroyer DCS 36/7 High Security COMBO Paper, CD, DVD, and Blu-ray Shredder
Press Release Distributed by PR.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 hours ago
- Yahoo
ATO- One of My Favorite Utilities in a Booming Market
Second-quarter earnings results and guidance updates are all in for CUI Portfolio recommendations. The big takeaway: The best-in-class are not just crushing it as businesses. They're setting up for even better to come over the next few years. One of my favorite names is Atmos Energy Corp. (ATO), writes Roger Conrad, editor of Conrad's Utility Investor. To get more articles and chart analysis from MoneyShow, subscribe to our .) Not every utility stock I track has made money so far in 2025. But the average return for stocks of the 41 companies represented in the portfolios is 13.4%, well ahead of the Big Tech-burdened S&P 500 Index (^SPX) year-to-date. (Editor's Note: Roger is speaking at the 2025 MoneyShow/TradersEXPO Orlando, scheduled for Oct. 16-18. Click HERE to register.) Atmos Energy Corp. (ATO) Utilities are providing the 'picks and shovels' for the ongoing Artificial Intelligence (AI) gold rush. There's reason to doubt some of the more expansive projections for future electricity demand. But actual company results and guidance show clearly that growth is already the fastest since the 1950s. The lowest-risk investments are in the regulated power and natural gas grid. These days, Capex is pre-approved by regulators and investment is usually recovered as incurred in rate riders. That's a huge change from the 1970s and 80s, when utilities did all the work and spending before regulators decided (with 20-20 hindsight) how much cost recovery to allow in rates as 'prudent.' It can take years to build a major power transmission line or natural gas pipeline. But most grid projects are completed in months, which means companies can keep tight control of costs. It adds up to extraordinarily predictable and robust earnings growth. Unfortunately, finding an energy distributor trading at a good entry point has been challenging the past couple years. See also: Gold: Why This "Least Techie" Asset is Surging in a Tech Boom My favorite in the sector is ATO. It just boosted its FY2025 (ending Sept. 30) earnings guidance for the third time this year. It's a great company. But if you buy the stock now, just know you're going to get a yield of barely 2%. More From SPX: Why No One Seems to Care About Tariffs Anymore HD: A Housing Sector Bellwether that Offers Solid Value Market Minute 8/12/25: Wall Street Breathes Easier After CPI
Business Wire
7 hours ago
- Business Wire
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)-- Zura Bio Limited (Nasdaq: ZURA) ('Zura Bio' or the 'Company'), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. 'The second quarter of 2025 marked continued progress across our clinical programs and organizational goals,' said Robert Lisicki, Chief Executive Officer of Zura Bio. 'We advanced our Phase 2 clinical study in systemic sclerosis and initiated a second Phase 2 clinical study in hidradenitis suppurativa. We also welcomed a new Chief Financial Officer as well as a new member of our board of directors, who bring valuable experiences and perspectives. As we look ahead, we remain focused on executing our strategy with discipline and care.' PIPELINE HIGHLIGHTS AND UPCOMING ANTICIPATED MILESTONES Tibulizumab Hidradenitis suppurativa In the second quarter of 2025, Zura Bio initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe HS. A topline data readout is anticipated in the third quarter of 2026. Systemic sclerosis The Company also continued to advance TibuSURE, a global Phase 2 clinical study evaluating tibulizumab in adults with SSc. A topline data readout is anticipated in the fourth quarter of 2026. Crebankitug Zura Bio continues to conduct preclinical and translational research on crebankitug to explore its potential in immune-mediated diseases where dual inhibition of interleukin-7 (IL-7) and thymic stromal lymphopoietin (TSLP) may offer therapeutic benefit. The Company is collaborating with academic researchers to guide future development decisions. Torudokimab Zura Bio is evaluating the potential role of torudokimab in inflammatory and respiratory diseases. The Company continues to monitor external clinical data from ongoing IL-33/ST2-targeted programs in asthma and chronic obstructive pulmonary disease, including Phase 2b and Phase 3 trials. An additional IL-33/ST2 data readout is expected in 2026. These findings may help inform future development plans for torudokimab. CORPORATE HIGHLIGHTS In May 2025, Dan Becker, M.D., Ph.D. joined the Board of Directors, bringing a strong background in immunology and biotechnology. In July 2025, Eric Hyllengren was appointed as Chief Financial Officer. With more than 20 years of experience in financial leadership within the life sciences sector, Mr. Hyllengren will help guide the Company's financial and operational planning. SECOND QUARTER 2025 FINANCIAL RESULTS Cash Position As of June 30, 2025, Zura Bio had cash and cash equivalents of $154.5 million. The Company anticipates that its existing cash and cash equivalents should be sufficient to support operations as currently planned through 2027. Research and Development (R&D) Expenses R&D expenses were $8.7 million for the second quarter of 2025, compared to $5.5 million for the same period in 2024. The increase of $3.2 million was primarily related to our continued advancement of our Phase 2 clinical studies evaluating tibulizumab in SSc and HS. Specifically, we incurred a $3.3 million increase in costs related to our SSc and HS clinical studies driven by an increase in contract research organization (CRO) expenses. These increases were partially offset by a $1.3 million reduction in manufacturing costs for our product candidates. R&D compensation costs increased by $0.7 million, reflecting additional headcount to support the growing development organization. General and Administrative (G&A) Expenses G&A expenses were $9.4 million for the second quarter of 2025, compared to $6.2 million for the same period in 2024. The $3.2 million year-over-year increase was primarily driven by a $2.0 million increase in compensation costs to support the expansion of administrative functions and a $1.2 million increase in external spend related to organizational growth as we continue to advance our clinical development programs. Net Loss Net loss for the second quarter of 2025 was $16.0 million, or $0.17 per share, compared to $10.3 million, or $0.17 per share, for the same period in 2024. ABOUT ZURA BIO Zura Bio is a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs. The Company's pipeline includes dual-pathway product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients. Zura Bio's lead product candidate, tibulizumab (ZB-106), is currently being evaluated in two separate Phase 2 clinical studies in adults, including TibuSURE for systemic sclerosis and TibuSHIELD for hidradenitis suppurativa. Additional product candidates, crebankitug (ZB-168) and torudokimab (ZB-880), have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions. For more information, please visit FORWARD-LOOKING STATEMENTS This communication includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believe,' 'predict,' 'potential,' 'continue,' 'strategy,' 'future,' 'opportunity,' 'would,' 'seem,' 'seek,' 'outlook,' 'goal,' 'mission,' and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this communication. These forward-looking statements in this release include, but are not limited to, statements regarding: Zura Bio's forecasts, including with respect to its cash resources; Zura Bio's expectations regarding funding, operating and working capital expenditures, business strategies and objectives; and expectations with respect to Zura Bio's development program, including its product candidates and the potential clinical benefits thereof, data readouts, regulatory matters, clinical studies and the design and timing thereof. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events are difficult or impossible to predict and could differ materially from those expressed or implied in such forward-looking statements, as a result of these risks and uncertainties, which include, but are not limited to: Zura Bio's expectations regarding its product candidates and their related benefits, and Zura Bio's beliefs regarding competing product candidates and products both in development and approved, may not be achieved; Zura Bio's vision and strategy may not be successful; the timing of key events and initiation of Zura Bio's studies, regulatory matters and release of clinical data may take longer than anticipated or may not be achieved at all; the potential general acceptability and maintenance of Zura Bio's product candidates by regulatory authorities, payors, physicians, and patients may not be achieved; Zura Bio's ability to attract and retain key personnel; Zura Bio's expectations with respect to its future operating expenses, capital requirements and needs for additional financing may not be achieved; Zura Bio has not completed any clinical trials, and has no products approved for commercial sale; Zura Bio has incurred significant losses since inception, and expects to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future; Zura Bio requires substantial additional capital to finance its operations, and if it is unable to raise such capital when needed or on acceptable terms, Zura Bio may be forced to delay, reduce, and/or eliminate one or more of its development programs or future commercialization efforts; Zura Bio may be unable to renew existing contracts or enter into new contracts; Zura Bio relies on third-party contract development manufacturing organizations for the manufacture of clinical materials; Zura Bio relies on contract research organizations, clinical trial sites, and other third parties to conduct its preclinical studies and clinical studies; Zura Bio may be unable to obtain regulatory approval for its product candidates, and there may be related restrictions or limitations of any approved products; Zura Bio may be unable to successfully respond to general economic and geopolitical conditions; Zura Bio may be unable to effectively manage growth; Zura Bio faces competitive pressures from other companies worldwide; Zura Bio may be unable to adequately protect its intellectual property rights; and other factors set forth in documents filed, or to be filed by Zura Bio, with the Securities and Exchange Commission (SEC), including the risks and uncertainties described in the 'Risk Factors' section of Zura Bio's Annual Report on Form 10-K for the year ended December 31, 2024, as supplemented by Zura Bio's Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025 and June 30, 2025, and other filings with the SEC. These risks and uncertainties may be amplified by health epidemics or other unanticipated global disruption events, including the conflict between Russia and Ukraine and the Israel-Hamas war and sanctions related thereto, international trade policies, including tariffs, inflation, increased interest rates, uncertain global credit and capital markets and disruptions in banking systems, and changes in regulations, which may continue to cause economic uncertainty. Zura Bio cautions that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Zura Bio gives no assurance that it will achieve its expectations. Zura Bio does not undertake or accept any obligation to update any forward-looking statements, except as required by law. ZURA BIO LIMITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (In thousands, except share and per share data) For the Three Months Ended For the Six Months Ended June 30, June 30, 2025 2024 2025 2024 Operating expenses: Research and development $ 8,704 $ 5,539 $ 19,178 $ 9,132 General and administrative 9,358 6,220 18,138 11,006 Total operating expenses 18,062 11,759 37,316 20,138 Loss from operations (18,062 ) (11,759 ) (37,316 ) (20,138 ) Other (income)/expense, net: Interest income (1,717 ) (2,196 ) (3,534 ) (3,411 ) Change in fair value of private placement warrants — 768 — 1,374 Other income, net (352 ) (2 ) (347 ) (25 ) Total other income, net (2,069 ) (1,430 ) (3,881 ) (2,062 ) Loss before income taxes (15,993 ) $ (10,329 ) (33,435 ) (18,076 ) Income tax benefit — — — — Net loss (15,993 ) (10,329 ) (33,435 ) (18,076 ) Accretion of redeemable noncontrolling interest to redemption value — (2,337 ) — (2,337 ) Adjustment of redeemable noncontrolling interest from redemption value to carrying value — — — 7,017 Net loss attributable to Class A Ordinary Shareholders of Zura $ (15,993 ) $ (12,666 ) $ (33,435 ) $ (13,396 ) Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted $ (0.17 ) $ (0.17 ) $ (0.36 ) $ (0.22 ) Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted 94,289,954 74,947,369 93,630,719 60,930,956 Expand
Axios
a day ago
- Axios
Exclusive: Northrop plans to quadruple chip output by 2030
There's a chip factory tucked between Baltimore city limits and BWI Airport. For something so high-profile, it's easy to miss. Why it matters: Northrop Grumman's Advanced Technology Lab in Linthicum Heights, Maryland, is pumping out precious, microscopic components at a time of surging stateside demand, questionable defense-industrial base fitness and broader international aggression. The company's chips can be found in F-16 and E-7 aircraft, Apache helicopters, G/ATOR radars, naval electronic warfare systems, drones, the James Webb telescope and more. Driving the news: Axios toured the lab — sterile "bunny suit" and all — in late July. The intrigue: Northrop is positioning itself as a domestic expert that plays well with others, including other defense contractors. That means greater supply chain visibility for buyers and users as well as cooperation with competitors. "The company sees a lot of value in us being able to supply our microelectronics capabilities to benefit the national interest. That's national security. That's economic security," David Shahin, senior manager of Northrop's microelectronics center, said in an interview. Zoom in: The company is bullish on advanced packaging, a process that consolidates component footprints, ultimately saving space and boosting performance. Think of it like mixed-use versus single-family residential zoning. "The promise of advanced packaging for microelectronics is now you can fabricate the best chips wherever you need to," Shahin said, "and you can join them together into something that puts the whole system ... into something that is a fraction of the size."
